title: Hepatitis G virus infection: clinical characteristics and response to interferon.
abstract: A new member of the Flaviviridae family has recently been cloned and completely sequenced. The new virus, tentatively named hepatitis G virus (HGV) and known to be closely related to GB virus C (GBV-C), is transmitted by blood and blood products, intravenous drug use and other behaviour associated with a high risk of parenteral exposure to blood. The association of the virus with hepatitis is demonstrated by the presence of raised liver transaminase (alanine aminotransferase, ALT) levels in patients infected with HGV in the absence of other identifiable causes of hepatitis. No patient sera from groups exposed to blood and blood products were found to be positive when tested for the presence of GBV-A or GBV-B sequences, two other recently described flaviviruses. Forty-five per cent of the HGV-infected patients investigated had normal ALT suggesting the existence of a normal carrier state. Persistent infection of up to 13 years duration was observed. Co-infection with hepatitis B or hepatitis C viruses (HBV and HCV) was commonly seen presumably because of shared risk factors. None of five patients with fulminant hepatic failure was positive for HGV infection. The virus is sensitive to interferon-alpha, but sustained responses were not seen with the treatment regimens used for HBV and HCV. Viral titres increased during immunosuppression following liver transplantation and the higher levels of viraemia were in one case accompanied by elavated ALT. Whether HGV (GBV-C) replicates in the liver in some or all cases remains to be established. Preliminary data suggest that it is present within peripheral blood lymphocytes.
authors.affiliation: Academic Department of Medicine, St. Mary's Hospital Medical School, Imperial College, London, UK.
authors.forename: P
authors.initials: P
authors.lastname: Karayiannis
authors.forename: S J
authors.initials: SJ
authors.lastname: Hadziyannis
authors.forename: J
authors.initials: J
authors.lastname: Kim
authors.forename: J M
authors.initials: JM
authors.lastname: Pickering
authors.forename: M
authors.initials: M
authors.lastname: Piatak
authors.forename: G
authors.initials: G
authors.lastname: Hess
authors.forename: A
authors.initials: A
authors.lastname: Yun
authors.forename: M J
authors.initials: MJ
authors.lastname: McGarvey
authors.forename: J
authors.initials: J
authors.lastname: Wages
authors.forename: H C
authors.initials: HC
authors.lastname: Thomas
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D018067:Flaviviridae / Q000235:genetics; D006509:Hepatitis B / Q000150:complications; D006526:Hepatitis C / Q000150:complications; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000150:complications / Q000628:therapy / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007963:Leukocytes, Mononuclear / Q000821:virology; D016031:Liver Transplantation / Q000009:adverse effects; D008297:Male; D012367:RNA, Viral / Q000097:blood; D012189:Retrospective Studies
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D012367:RNA, Viral